Description:
The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at
increased risk for development of breast cancer.
Title
- Brief Title: Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
- Official Title: Flaxseed Lignan as a Prevention Strategy for Pre-Menopausal Women at High Risk for Development of Breast Cancer
Clinical Trial IDs
- ORG STUDY ID:
12377
- NCT ID:
NCT01276704
Conditions
Interventions
Drug | Synonyms | Arms |
---|
Placebo | | Placebo |
secoisolariciresinol | SDG | flaxseed lignan, SDG |
Purpose
The investigators will study the effect of 12 months of SDG (Brevail) vs placebo on women at
increased risk for development of breast cancer.
Detailed Description
The investigators would like to see if women at increased risk for breast cancer are likely
to tolerate SDG daily for 12 months without significant side effects or changes in their
menstrual cycles. The investigators would also like to determine if Brevail® can reduce
breast cell proliferation in pre-menopausal women.
Trial Arms
Name | Type | Description | Interventions |
---|
flaxseed lignan, SDG | Experimental | Secoisolariciresinol diglycoside | |
Placebo | Placebo Comparator | Matched Placebo | |
Eligibility Criteria
PARTICIPANT SELECTION
- Risk Level Required for RPFNA Screening for Eligibility
- Given the low probability of side effects and the desire to be able to generalize
results to a moderate as well as high risk population, the target cohort is
pre-menopausal women who have a relative risk for breast cancer which is 2-fold
or greater than that of the average woman in their age group by virtue of any one
of the following conditions:
- A 1st or 2nd degree relative with breast cancer diagnosed under the age of 60
- A prior biopsy indicating proliferative breast disease, atypical hyperplasia, or LCIS
- Multiple prior breast biopsies regardless of histology
- 50% or higher estimated mammographic density on visual inspection
- Prior or current RPFNA evidence of atypia
- Known carrier of a BRCA1 or 2 mutation.
- Age, Life-Style and Medical Eligibility Criteria for Tissue Screening
Candidates for tissue screening for this study are pre-menopausal women who meet the risk
criteria above and all of the following demographic and medical criteria:
- Age 21 to 49 (limiting the maximum age to 49 will reduce the possibility of reduction
in Ki-67 due to entry into menopause transition during the study).
- Stable hormonal status for the previous 6 months (has not stopped or started oral
contraceptives, or experienced lactation or pregnancy) and willing to maintain same
status while on study.
- BMI < 40 kg/m2.
- Has had at least 4 menstrual cycles in past year
- If regularly undergoing screening mammography, must have been performed within 9
months prior to baseline RPFNA, and interpreted as not suspicious for breast cancer
- Breast exam interpreted as normal (not suspicious for cancer).
- Exclusion Criteria for Screening RPFNA and Study Participation
Candidates are ineligible for tissue screening if they meet any of the following
conditions:
- Consumption of systemic antibiotics during the 3 weeks prior to baseline RPFNA.
Systemic antibiotics reduce intestinal bacteria and thus the ability to convert SECO
to ENL.
- Consumption of supplements containing SDG (flaxseed or sesame seed) during the 3 weeks
prior to baseline RPFNA. ( Consumption of foods containing flaxseed or sesame seed are
OK.)
- Use of any selective estrogen receptor modulator or aromatase inhibitor (tamoxifen,
raloxifene, arzoxifene, acolbifene, anastrozole, exemestane, letrozole) within the
previous 6 months.
- Currently enrolled on an interventional investigational study.
- Bilateral breast implants.
- Invasive breast cancer or other invasive cancer diagnosis within five years.
- Metastatic malignancy of any kind.excluding Hodgkin's or non-Hodgkin's lymphoma.
- Current anticoagulant use.
- Consumption of coumadin, fish oil, or other anticoagulants during the 3 weeks prior to
baseline RPFNA.
- Any other condition or intercurrent illness that in the opinion of the investigator
makes the subject a poor candidate for RPFNA or the trial.
- Inclusion Criteria for Study Entry
- RPFNA performed in the follicular portion (day 1-10) of the menstrual cycle. Note that
day 1 is defined as the first day of bleeding.
- RPFNA specimen exhibits hyperplasia +/- atypia (Masood score of ≥13) with ≥500 cells
on the cytology slide.
- Ki-67 ≥2% positivity (≥500 cells).
- Willing to continue without oral contraceptives throughout the duration of the study
participation (12 months). Non-oral contraceptives are permissible. If heterosexually
active, must be agreeable to use some non-hormonal form of contraception during the
trial or husband or partner must have had a vasectomy. (Safety of SDG during pregnancy
has not been documented).
- Have reasonable organ function as documented by metabolic chemistry profile.
- Willing to undergo a history and physical at baseline and 12 months and be contacted
periodically by the trial coordinator during the 12 month study period.
- Willing to have blood drawn at baseline and twelve months.
- Able to understand and willing to provide informed consent for the RPFNA's and study
participation.
Maximum Eligible Age: | 49 Years |
Minimum Eligible Age: | 21 Years |
Eligible Gender: | Female |
Healthy Volunteers: | Accepts Healthy Volunteers |
Primary Outcome Measures
Measure: | The primary objective is to determine if women randomized to 12 months of SDG exhibit greater change in the proportion of breast epithelial cells expressing benign breast tissue than do women randomized to placebo. |
Time Frame: | 12 months |
Safety Issue: | |
Description: | The primary objective is to determine if women randomized to 12 months of SDG exhibit greater change in the proportion of breast epithelial cells expressing the proliferation marker Ki- 67/MIB-1 in hyperplastic benign breast tissue than do women randomized to placebo. |
Secondary Outcome Measures
Measure: | to determine if 12 months of SDG is associated with favorable modulation of other risk biomarkers |
Time Frame: | 12 months |
Safety Issue: | |
Description: | Other biomarkers will be assessed so as to provide explanation for the observed responses. |
Measure: | to determine if Ki-67 and modulation of other risk biomarkers is correlated with related to change in blood or urine lignans |
Time Frame: | 6 months and 12 months |
Safety Issue: | |
Description: | Biomarker modulation will be correlated to blood lignan levels achieved. |
Measure: | to determine impact or potential impact on quality of life |
Time Frame: | 12 months |
Safety Issue: | |
Description: | to determine impact or potential impact on quality of life as measured by the BPQ breast pain questionnaire (a modified McGill Pain questionnaire), The Breast Cancer Prevention Trial (BCPT) Symptom Checklist a menstrual diary for cyclicity and cycle length and antimullerian hormone (AMH), a measure of follicular reserve |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | Carol Fabian, MD |
Last Updated
January 17, 2018